|
Press Releases
March 24, 2010
Provectus Pharmaceuticals to Present at CFA Society of Nevada on March 31, 2010
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT)
announces that Craig Dees, Ph.D., CEO, will appear at the CFA Society of Nevada.
Read the complete article here.
March 18, 2010
Phase 2 Data on Provectus's PV-10 To Be Presented at the 2010 ASCO Scientific Program on June 4 - 8 in Chicago
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical
Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois.
Read the complete article here.
March 15, 2010
Data Highlights Involvement of Immune System in Response to Provectus's PV-10 Therapy and Its Role in the Bystander Effect
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that Dr. Sanjiv Agarwala, in his presentation at the Seventh International Symposium on Melanoma and
Other Cutaneous Malignancies on March 12, 2010, commented on the involvement of the immune system in response to PV-10
therapy and its role in the "bystander effect" in treating metastatic melanoma. Dr. Agarwala's presentation, entitled
"Chemoablation in Melanoma: An Update," was given in the session entitled "Unique Approaches to Melanoma Therapy."
Read the complete article here.
March 12, 2010
Provectus Pharmaceuticals Closes $7.5 Million Private Placement
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that it has received gross proceeds of approximately $7.5 million in a private placement offering to
institutional and accredited investors.
Read the complete article here.
March 9, 2010
Provectus Pharmaceuticals Executes Purchase Agreements for Approximately $5.3 Million Private Placement
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that it has signed agreements with various institutional and accredited investors for the private placement of an aggregate of approximately
7.1 million shares of its convertible preferred stock and warrants to purchase approximately 3.55 million shares of its common stock at an exercise price of
$1.00 per share pursuant to a Securities Purchase Agreement. The Company will receive gross proceeds of $5.3 million. The shares to be issued to the investors
and the shares underlying the warrants have not been and will not be registered under the Securities Act of 1933, and may not be offered or sold in the
United States absent registration or an applicable exemption from registration requirements.
Read the complete article here.
March 8, 2010
Dr. Sanjiv Agarwala to Present Update on Provectus' PV-10
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB:
PVCT
http://www.pvct.com)
announced today that Dr. Sanjiv Agarwala, Principal Investigator for Provectus' Phase 2 PV-10 trial site at St. Luke's Hospital & Health Network in Bethlehem, PA,
will present an update on the Company's ongoing Phase 2 trial of PV-10 for metastatic melanoma at the Seventh International Symposium on Melanoma and Other
Cutaneous Malignancies on March 12, 2010, in New York City.
Read the complete article here.
|
